Client First Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.65M Buy
2,289
+3
+0.1% +$3.54K 1.26% 14
2026
Q2
$2.74M Buy
2,286
+3
+0.1% +$3.06K 1.16% 13
2026
Q1
$2.1M Buy
2,283
+4
+0.2% +$4.05K 1.09% 10
2025
Q4
$2.45M Buy
2,279
+3
+0.1% +$2.87K 1.28% 9
2025
Q3
$1.74M Sell
2,276
-190
-8% -$141K 0.89% 19
2025
Q2
$1.92M Buy
2,466
+5
+0.2% +$3.88K 1.18% 12
2025
Q1
$2.03M Buy
2,461
+4
+0.2% +$3.33K 1.38% 7
2024
Q4
$1.9M Buy
2,457
+4
+0.2% +$3.31K 1.22% 10
2024
Q3
$2.17M Buy
2,453
+4
+0.2% +$3.6K 1.66% 8
2024
Q2
$2.22M Buy
2,449
+3
+0.1% +$2.4K 1.72% 8
2024
Q1
$1.9M Buy
2,446
+5
+0.2% +$3.56K 1.51% 9
2023
Q4
$1.42M Buy
+2,441
New +$1.42M 1.38% 14

Other funds holding LLY

Client First Investment Management's LLY Position: Q3 2026 in Review

Client First Investment Management increased its Eli Lilly (LLY) stake by 0.13% in Q3 2026, buying an estimated $3.54K and bringing the position to 2,289 shares worth $2.65M. The position accounts for 1.26% of the portfolio, ranked #14.

Client First Investment Management first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.74M in Q2 2026. 660 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Client First Investment Management held 2,289 shares of Eli Lilly worth $2.65M as of Q3 2026.
  • Client First Investment Management bought 3 Eli Lilly shares in Q3 2026, an estimated $3.54K.
  • Eli Lilly made up 1.26% of Client First Investment Management's portfolio in Q3 2026, its #14 holding.
  • Client First Investment Management first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • Client First Investment Management's Eli Lilly position peaked at $2.74M in Q2 2026.
  • 660 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Client First Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.